Collegium Pharmaceutical (COLL) EBT Growth (1y) (2015 - 2026)
Powered by 
Analysis
Collegium Pharmaceutical (COLL) EBT Growth (1y) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | 3.94% |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | 175.29% |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | -113.66% |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | -5.78% |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | -121.45% |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | -15.76% |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | - |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 34.68% |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | -8.74% |
| 10 | Collegium Pharmaceutical | 753.09 Mn | 603.77 Mn | 110.29 Mn | -179.48% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -179.48% |
| Mar 31, 2026 | 500.26% |
| Dec 31, 2025 | 68.14% |
| Sep 30, 2025 | 178.79% |
| Jun 30, 2025 | -41.49% |
| Mar 31, 2025 | -91.48% |
| Dec 31, 2024 | -63.03% |
| Sep 30, 2024 | -45.87% |
| Jun 30, 2024 | 63.49% |
| Mar 31, 2024 | 308.59% |
| Dec 31, 2023 | 699.54% |
| Sep 30, 2023 | 1,909.99% |
| Jun 30, 2023 | 367.79% |
| Mar 31, 2023 | -10.83% |
| Dec 31, 2022 | 79.96% |
| Sep 30, 2022 | -84.15% |
| Jun 30, 2022 | -160.47% |
| Mar 31, 2022 | -202.38% |
| Dec 31, 2021 | -635.33% |
| Sep 30, 2021 | -21.87% |